DGAP-News

STRATEC reports on first three months of 2013

DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC reports on first three months of 2013

07.05.2013 / 07:27

---------------------------------------------------------------------

STRATEC reports on first three months of 2013

- Sales increase by 14.1% to EUR 29.2 million in Q1/2013
(Q1/2012: EUR 25.6 million*)
- EBIT margin of 15.1% in Q1/2013, up from 12.2% in Q4/2012
(Q1/2012: 17.0%*)
- Consolidated net income of EUR 3.5 million in Q1/2013
(+3.1%; Q1/2012: EUR 3.4 million)
- Earnings per share of EUR 0.30 in Q1/2013
(+3.4%; Q1/2012: EUR 0.29)
- Updated company forecast planned for release by end of H1/2013

Birkenfeld, May 7, 2013

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) today
announced its results for the period from January 1, 2013 to March 31, 2013
upon the publication of its Interim Report as of March 31, 2013.

Key figures (EUR 000s)     01.01.- 03.31.2013   01.01.- 03.31.2012   Change

Sales                                  29,173              25,573*   +14.1%

EBIT                                    4,406                4,349    +1.3%

EBIT margin (%)                          15.1                17,0*      ---

Consolidated net income                 3,544                3,439    +3.1%

Earnings per share (EUR)                 0.30                 0.29    +3.4%

* 2012 figure adjusted for a one-off item of EUR 3.3 million due to an
income-neutral reclassification from unfinished services and prepayments
received upon the write-down of a development project. On an unadjusted
basis, sales for the first quarter of 2012 amounted to EUR 28.8 million and
the corresponding EBIT margin amounted to 15.1%.


Financial performance
Sales performed positively in the first quarter of 2013 and increased
year-on-year by 14.1%. This growth was driven both by sound developments in
the volume of analyzer systems delivered, and by a recovery in the service
parts business. The share of sales generated with servicing parts continued
to recover compared with 2012 as a whole, and rose significantly compared
with the weak final quarter of 2012. Due not least to this factor, the EBIT
margin of 15.1% for the first three months of 2013 was improved compared to
the overall 2012 financial year (14.4%), and most visibly improved when
compared to the final quarter of last year (12.2%). Based on current
developments, STRATEC expects the positive trend observed so far in 2013 to
date to continue. At EUR 3.5 million, consolidated net income was up 3.1%